logo-loader

TRACON Pharmaceuticals announces milestone dosing of 36th patient in ENVASARC pivotal trial

Published: 14:38 26 Jul 2022 EDT

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer says the enrollment of the 36th patient in its ENVASARC pivotal trial for envafolimab will enable the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed.

He said this is expected to occur in the fourth quarter of this year.

Theuer noted that TRACON is currently ahead of the enrollment projection that would allow for full accrual of the 160 planned patients dosed with 600 mg of envafolimab before the end of 2023.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

28 minutes ago